With most pharmaceutical companies currently embarking on the same omnichannel strategy, from a doctor’s perspective, this results in a relentless deluge of emails, webinar invites and promotional material. So, what should pharmaceutical companies and their representatives consider going forward?
With many GPs no longer seeing sales representatives, pharmaceutical companies should be prepared to engage and support GPs under a digitally led model.
COVID-19 created opportunities for pharmaceutical companies to find new ways to engage with GPs. While face-to-face rep visits are likely to remain integral, it’s clear that increasingly time-poor GPs are seeking synthesised, relevant insights in a timely manner and want to drive the engagement on their terms.